XOMA Royalty Corporation operates as a biotech royalty aggregator in the US and Asia Pacific. It has a portfolio of economic rights to milestone and royalty payments from partnered therapeutics. The company also focuses on early-stage clinical assets with commercial sales potential licensed to partners. Additionally, it acquires late-stage clinical or commercial asset revenue streams.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |